Goldman Sachs: Curing Patients’ Illnesses Is Bad for Business
In a recent report for its biotech clients, investment bank Goldman Sachs frowned on a new type of genome therapy that could permanently cure disease. As CNBC originally reported, Goldman Sachs published…

